In order to evaluate tumor BRCA1/2 (tBRCA) testing performed in our Molecular and Genomic Diagnostics Unit (MGDUnit) as a predictive biomarker of response to platinum-based-chemotherapy and PARP-inhibitors in ovarian cancer patients [5], we recently joined the disease-based Somatic Ovarian 2020 scheme of the European Molecular Genetics Quality Network (EMQN) [6]. This evidence concerns the gene BRCA1 and ovarian cancer.